These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 17915620)

  • 1. Multicentric Castleman disease with secondary AA renal amyloidosis, nephrotic syndrome and chronic renal failure, remission after high-dose melphalan and autologous stem cell transplantation.
    Ogita M; Hoshino J; Sogawa Y; Sawa N; Katori H; Takemoto F; Ubara Y; Hara S; Miyakoshi S; Takaichi K
    Clin Nephrol; 2007 Sep; 68(3):171-6. PubMed ID: 17915620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission of nephrotic syndrome after removal of localized Castleman's disease.
    Keven K; Nergizoğlu G; Ateş K; Erekul S; Orhan D; Ertürk S; Tulunay O; Karatan O; Ertuğ AE
    Am J Kidney Dis; 2000 Jun; 35(6):1207-11. PubMed ID: 10845836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A long-term remission of renal amyloidosis with nephrotic syndrome after autologous peripheral blood stem-cell transplantation.
    Ogawa K; Ikeda K; Furukawa M; Harada-Shirado K; Mashimo Y; Takahashi H; Matsumoto H; Kimura S; Shichishima-Nakamura A; Ohkawara H; Hashimoto Y; Asahi K; Noji H; Ohto H; Takeishi Y
    Fukushima J Med Sci; 2010 Dec; 56(2):151-6. PubMed ID: 21502717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of nephrotic syndrome due to systemic AL amyloidosis after autologous stem cell transplantation: renal response is an important therapeutic end point.
    Akay OM; Sahin G; Kabukcuoglu S; Yalcin AU; Gulbas Z
    Clin Nephrol; 2008 Apr; 69(4):294-7. PubMed ID: 18397705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two cases of idiopathic multicentric Castleman disease with nephrotic syndrome treated with tocilizumab.
    Furutera N; Fukunaga N; Okita J; Suzuki T; Suenaga Y; Oyama Y; Aoki K; Fukuda A; Nakata T; Uesugi N; Daa T; Hisano S; Shibata H
    CEN Case Rep; 2021 Feb; 10(1):35-41. PubMed ID: 32715375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab histologically improved AA renal amyloidosis in a patient with multicentric Castleman disease: A case report
.
    Yamada Y; Ueno T; Irifuku T; Nakashima A; Doi S; Ichinohe T; Masaki T
    Clin Nephrol; 2018 Sep; 90(3):232-236. PubMed ID: 29701172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.
    Dember LM; Sanchorawala V; Seldin DC; Wright DG; LaValley M; Berk JL; Falk RH; Skinner M
    Ann Intern Med; 2001 May; 134(9 Pt 1):746-53. PubMed ID: 11329232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary amyloidosis of the kidney.
    Shafique S; Wetmore J; Almehmi A
    W V Med J; 2010; 106(1):22-4. PubMed ID: 20088306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nephrotic Syndrome Caused by AA Amyloidosis Secondary to Unicentric Castleman's Disease:Report of One Case].
    You RL; Wen YB; Wang J; Ma J; Chen LM; Li XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Jun; 44(3):540-544. PubMed ID: 35791957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful reduced intensity allogeneic stem cell transplantation for systemic AL amyloidosis.
    Imamura T; Ogata M; Kohno K; Tomo T; Ohtsuka E; Kikuchi H; Kadota J
    Am J Hematol; 2006 Apr; 81(4):281-3. PubMed ID: 16550508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [White blood cell lysis syndrome after autologous peripheral blood stem cell transplantation in the treatment of renal AL amyloidosis. Case report].
    Gatica A; Bertin P; Tagle R
    Rev Med Chil; 2006 Jun; 134(6):763-6. PubMed ID: 17130952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced intensity allogeneic stem cell transplantation for systemic primary amyloidosis refractory to high-dose melphalan.
    Kawai Y; Kinoshita K; Arai H; Kuwata A; Fukuoka Y; Yamaoka M; Imamura S; Tsutani H; Ueda T
    Eur J Haematol; 2004 Jun; 72(6):448-50. PubMed ID: 15128426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation.
    Gono T; Matsuda M; Dohi N; Hoshi K; Tada T; Sakashita K; Koike K; Aizawa M; Ikeda S
    Intern Med; 2003 Jan; 42(1):72-7. PubMed ID: 12583623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of nephrotic syndrome due to reactive amyloidosis (AA-type) after excision of localized Castleman's disease.
    Perfetti V; Bellotti V; Maggi A; Arbustini E; De Benedetti F; Paulli M; Marinone MG; Merlini G
    Am J Hematol; 1994 Jul; 46(3):189-93. PubMed ID: 7910717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary amyloidosis associated with Castleman's disease.
    Tanaka K; Horita M; Shibayama H; Seike M; Itoh Y; Hamaguchi K; Sato Y; Sakata T; Ishida T
    Intern Med; 1995 Feb; 34(2):122-6. PubMed ID: 7727877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement.
    Gertz MA; Leung N; Lacy MQ; Dispenzieri A
    Kidney Int; 2005 Oct; 68(4):1464-71. PubMed ID: 16164623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Castleman's disease with renal amyloidosis and nephrotic syndrome.
    Arinsoy T; Yilmaz M; Ataoğlu O; Bali M; Sindel S
    Nephrol Dial Transplant; 1997 Dec; 12(12):2713-6. PubMed ID: 9430878
    [No Abstract]   [Full Text] [Related]  

  • 20. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
    Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
    Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.